GRIN2B and Dyskinesia: However, preclinical investigations suggest that these non-dopaminergic treatments, i.e. Adenosine A2A (A2A) and NMDA receptor subunit NR2B (NR2B) antagonist drugs, offer the great advantage of being devoid of any pro-dyskinetic effects [14], i.e. unlike L-DOPA their use is not expected to induce dyskinesia [15, 16].